Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.87 |
| ▸ | LMNA | P02545 | 2/20 | 0.87 |
| ▸ | NT5E | P21589 | 2/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.87 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.66 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.66 |
| ▸ | EGLN3 | Q9H6Z9 | 3/20 | 0.66 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.66 |
| ▸ | ALB | P02768 | 2/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.60 |
| ▸ | GLI1 | P08151 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | DPP4 | P27487 | 1/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.60 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.60 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13908801 | 1.00 | GPBAR1 (0.87) | GPBAR1LMNANT5ESMN1; SMN2EGLN2 | |
| SCHEMBL14259781 | 1.00 | GPBAR1 (0.87) | GPBAR1LMNANT5ESMN1; SMN2EGLN2 | |
| SCHEMBL13814591 | 1.00 | GPBAR1 (0.87) | GPBAR1LMNANT5ESMN1; SMN2EGLN2 | |
| Betunolic Acid SCHEMBL10062172 | 0.93 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2EGLN2 | |
| Betunolic Acid SCHEMBL14397742 | 0.93 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2EGLN2 | |
| Betunolic Acid SCHEMBL13814592 | 0.93 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2EGLN2 | |
| Betunolic Acid SCHEMBL14111993 | 0.93 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2EGLN2 | |
| Betunolic Acid SCHEMBL14436770 | 0.93 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2EGLN2 | |
| Betunolic Acid SCHEMBL13573800 | 0.93 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2EGLN2 | |
| Betunolic Acid SCHEMBL13098064 | 0.93 | GPBAR1 (1.00) | GPBAR1LMNANT5ESMN1; SMN2EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-8889854-B2 | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| US-8846647-B2 | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130296554-A1 | C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2013-11-07 | — | — | US | disclosed |
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035318-A1 | C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, CDK17 | GPBAR1 3478/4885LMNA 2166/4885NT5E 3874/4885 |
| US-20130296554-A1 | C-17 BICYCLIC AMINES OF TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, CDK17, UGT2B17 | GPBAR1 1757/4885LMNA 2123/4885NT5E 2524/4885 |
| US-20160151387-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | GPBAR1 3675/4885LMNA 2154/4885NT5E 3631/4885 |
| US-20140343000-A1 | COMPOSITIONS HAVING C-17 AND C-3 MODIFIED TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY | CYP51A1, UGT2B17, HSD17B7 | GPBAR1 3675/4885LMNA 2154/4885NT5E 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.